UPDATE: Hedge Fund Manger Kyle Bass Wins Right to Challenge Four Patents on Acorda's (ACOR) Ampyra

March 11, 2016 2:53 PM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - March 11, 2016 3:00 PM EST)

Hedge fund manager Kyle Bass' Coalition for Affordable Drugs won the right to challenge Acorda Therapeutics (NASDAQ: ACOR) patents 8663685 and 8440703 on Ampyra, according to several reports reports, including Bloomberg. The Patent Trial and Appeals Board said the hedge fund manager has a reasonable likelihood of winning its argument.

Patents are set to expire in 2025.

Update: PTAB also agreed to review Ampyra patents 8354437 and 8007826.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hedge Funds, Hot Corp. News, Litigation, Trader Talk

Related Entities

Hedge Funds